Moore RD - Search Results

1

Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era.

Calkins KL, Chander G, Joshu CE, Visvanathan K, Fojo AT, Lesko CR, Moore RD, Lau B. Calkins KL, et al. Among authors: moore rd. JAMA Oncol. 2020 Feb 1;6(2):227-235. doi: 10.1001/jamaoncol.2019.4648. JAMA Oncol. 2020. PMID: 31804663 Free PMC article.

2

Anemia in HIV-infected patients receiving highly active antiretroviral therapy.

Moore RD, Forney D. Moore RD, et al. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):54-7. doi: 10.1097/00042560-200201010-00007. J Acquir Immune Defic Syndr. 2002. PMID: 11782590

3

Association of medical insurance and other factors with receipt of antiretroviral therapy.

Keruly JC, Conviser R, Moore RD. Keruly JC, et al. Among authors: moore rd. Am J Public Health. 2002 May;92(5):852-7. doi: 10.2105/ajph.92.5.852. Am J Public Health. 2002. PMID: 11988459 Free PMC article.

4

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Sulkowski MS, et al. Among authors: moore rd. JAMA. 2002 Jul 10;288(2):199-206. doi: 10.1001/jama.288.2.199. JAMA. 2002. PMID: 12095384

5

Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort.

Perez JL, Moore RD. Perez JL, et al. Among authors: moore rd. Clin Infect Dis. 2003 Jan 15;36(2):212-8. doi: 10.1086/345669. Epub 2003 Jan 6. Clin Infect Dis. 2003. PMID: 12522755

6

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.

Sterling TR, Chaisson RE, Moore RD. Sterling TR, et al. Among authors: moore rd. Clin Infect Dis. 2003 Mar 15;36(6):812-5. doi: 10.1086/367934. Epub 2003 Feb 27. Clin Infect Dis. 2003. PMID: 12627368

7

Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings.

Spacek LA, Griswold M, Quinn TC, Moore RD. Spacek LA, et al. Among authors: moore rd. AIDS. 2003 Jun 13;17(9):1311-7. doi: 10.1097/00002030-200306130-00005. AIDS. 2003. PMID: 12799552

8

Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study.

Lucas GM, Chaisson RE, Moore RD. Lucas GM, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):321-8. doi: 10.1097/00126334-200307010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12843742

9

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Sethi AK, et al. Among authors: moore rd. Clin Infect Dis. 2003 Oct 15;37(8):1112-8. doi: 10.1086/378301. Epub 2003 Sep 19. Clin Infect Dis. 2003. PMID: 14523777

10

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: moore rd. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

925 results

Search Page

Filters